ID   VM7Luc4E2
AC   CVCL_6571
SY   BG1Luc4E2; BG-1Luc4E2; BG1Luc4E(2); BG1-ER
DR   Wikidata; Q54796232
RX   DOI=10.1787/9789264185395-en;
RX   PubMed=10900408;
RX   PubMed=26139245;
CC   Problematic cell line: Contaminated. Shown to be a MCF-7 derivative ( Originally thought to be a BG1 (Cellosaurus=CVCL_6570) derivative.
CC   Population: Caucasian.
CC   Biotechnology: Cell line developed for VM7Luc ER TA (VM7Luc Estrogen Receptor TransActivation) bioassay which was formerly known as BG1Luc ER TA (BG1Luc Estrogen Receptor TransActivation).
CC   Biotechnology: Used in the Organisation for Economic Co-operation and Development (OECD) detection of estrogenic/antiestrogenic chemicals test method 457 (DOI=10.1787/9789264185395-en).
CC   Characteristics: Emits measurable light in response to estrogen and estrogen-like substances. Used for identifying estrogen receptor agonists and antagonists.
CC   Characteristics: Acts through the activation of a luciferase reporter gene under the control of estrogen response elements (EREs) upstream of the mouse mammary tumor viral (MMTV) promoter.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Transfected with: UniProtKB; P08659; Firefly luciferase.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0031 ! MCF-7
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 22
RX   DOI=10.1787/9789264185395-en;
RT   "Test No. 457: BG1Luc estrogen receptor transactivation test method for
RT   identifying estrogen receptor agonists and antagonists.";
RL   (In) OECD guidelines for the testing of chemicals, Section 4; pp.1-26; OECD Publishing; Paris (2012).
RX   PubMed=10900408;
RA   Rogers J.M., Denison M.S.;
RT   "Recombinant cell bioassays for endocrine disruptors: development of a
RT   stably transfected human ovarian cell line for the detection of
RT   estrogenic and anti-estrogenic chemicals.";
RL   In Vitro Mol. Toxicol. 13:67-82(2000).
RX   PubMed=26139245; DOI=10.1002/etc.3146;
RA   Brennan J.C., Bassal A., He G.-C., Denison M.S.;
RT   "Development of a recombinant human ovarian (BG1) cell line containing
RT   estrogen receptor alpha and beta for improved detection of
RT   estrogenic/antiestrogenic chemicals.";
RL   Environ. Toxicol. Chem. 35:91-100(2016).